Rezolute, Inc. (RZLT)
Nasdaq · Healthcare · Biotechnology
$4.33+7.98%as of Oct 6, 2026, 7:35 AM ET
- Market cap
- $419M
- 52-week range
- $1.07 – $11.46
- 52-week change
- −54.22%
- EPS (trailing)
- −$0.75
- Analyst rating
- 1.4 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Jun 2026
- Net income
- −$77.6M
- Diluted EPS
- −$0.75
From the company’s annual report on SEC EDGAR.
About Rezolute, Inc.
Rezolute, Inc., a late-stage rare disease company, focuses developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism (HI) in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody which is in Phase 3 clinical trial to treat tumor HI indication, as well as congenital HI. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Headquarters: Redwood City, United States · 58 employees · rezolutebio.com